Earnings Call · Q3 FY2025·2025-11-14

Q3 25EPS -100.00%*·Rev n/aQ2 25EPS -45.45%·Rev n/aQ1 25EPS 0.00%·Rev n/aQ4 24EPS +50.00%·Rev n/a⚠ consensus missing

Iterum Therapeutics plc ITRMF

Kevin Dalton — Senior Director of Legal Affairs

Corey N. Fishman — Chief Executive Officer

Christine Coyne — Role not explicitly stated, likely in Marketing or Market Access

Judith M. Matthews — Chief Financial Officer

−16.1%1d on move date−16.1% vs SPY3d−29.3%5d−33.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ITRMF calls or request research access.

More ITRMF calls Browse calls Request research access